Predicting Success: The Easiest, And Hardest Routes To Market
Executive Summary
A new analysis from BIO, Informa Pharma Intelligence and QLS looks at clinical drug development activity from the past decade, looking at the most (and least) successful areas. Infographic depicts key trends and details.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
Complexity Has Benefits: Data Show Biologics, Targeted Agents Have Better Approval Prospects
Biologics have 9.1% likelihood of making it through the clinic to approval, compared to 5.7% for new molecular entities, according to an analysis of 10 years of Biomedtracker drug development data by BIO, Informa Pharma Intelligence and QLS.
Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.
Need a specific report? 1000+ reports available
Buy Reports